Keiko Katayose

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

Kotaro Shide, Haruko Shimoda, Takashi Kumano et al. · Leukemia · 2007 · 169 citations · Full text

Medicine, Hematology, Molecular Genetics +11

TET2 is essential for survival and hematopoietic stem cell homeostasis

Kotaro Shide, Takuro Kameda, Haruko Shimoda et al. · Leukemia · 2012 · 80 citations

Life Sciences, Cell Biology, Hematology +9

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

Tomonori Hidaka, Kotaro Shide, Haruko Shimoda et al. · European Journal Of Haematology · 2009 · 29 citations · Full text

Medicine, Hematology, Pathology +16

Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma

Takuro Kameda, Kotaro Shide, Haruko Shimoda et al. · International Journal of Hematology · 2010 · 18 citations

Life Sciences, Genetics, Oncology +13

Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.

Kotaro Shide, Takuro Kameda, Vadim Markovtsov et al. · Blood · 2009 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +9